An easy and reliable whole blood freezing method for flow cytometry immuno-phenotyping and functional analyses

Cecile Braudeau1,2, Nina Salabert-Le Guen1,2, Justine Chevreuil1,2

  • 1Laboratoire d'Immunologie, CIMNA, LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.

Insights

A new protocol for whole blood freezing using CryoStor® CS10 enables reliable immune monitoring in multicenter clinical trials. This method preserves key immune cell populations and intracellular markers, overcoming limitations of fresh sample analysis.

Area of Science:

  • Immunology
  • Cell Biology
  • Clinical Research

Background:

  • Flow cytometry immune profiling is limited by fresh blood sample constraints.
  • Cryopreservation of peripheral blood mononuclear cells (PBMC) requires specialized facilities, hindering multicenter studies.
  • Simplified whole blood freezing methods are needed to overcome these limitations.

Purpose of the Study:

  • To describe an optimized protocol for rapid whole blood freezing using CryoStor® CS10.
  • To compare cellular viability and composition of cryopreserved whole blood to fresh samples and frozen PBMC.
  • To validate the preservation of immune cell populations and intracellular markers for clinical applications.

Main Methods:

  • Developed an optimized protocol for rapid whole blood freezing with CryoStor® CS10.
  • Utilized flow cytometry to analyze cellular viability and composition.
  • Compared cryopreserved whole blood to matched fresh blood and fresh/frozen PBMC.

Main Results:

  • Leukocyte viability exceeded 75% with partial neutrophil loss.
  • Preserved viable T cells, NK cells, monocytes, dendritic cells, and eosinophils.
  • Validated analysis of intracellular markers (FOXP3, Helios) and cytokine production (IFNg, IL-4, IL-17A, IL-1b, IL-6, TNFa).

Conclusions:

  • The protocol offers a robust method for immune monitoring using cryopreserved whole blood.
  • Enables reliable immune monitoring in multicenter clinical trials.
  • Provides new opportunities for designing future clinical studies.
Abstract